Can the Hypotriglyceridemic Effect of Fish Oil Concentrate Be Sustained?
- 1 March 1989
- journal article
- research article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 110 (5) , 346-352
- https://doi.org/10.7326/0003-4819-110-5-346
Abstract
Study Objective: To determine whether high doses of fish oil concentrate followed by low-dose maintenance therapy can sustain the initial plasma triglyceride reductions. Design: Before-and-after trial with 3-month treatment periods. Setting: Outpatient lipid clinic at a university medical center. Patients: Sixteen patients with hypertriglyceridemia recruited from the General Internal Medicine Clinics. Five had concomitant hypercholesterolemia (type IIb). Intervention: Fish oil supplementation at two doses. After basal measurements, 9.8 g/d omega-3 fatty acids were provided for study months 1 to 3, and 3.9 g/d were provided for study months 4 to 6. Measurements and Main Results: Blood was drawn monthly and plasma was analyzed for levels of triglycerides, low-density-lipoprotein (LDL) cholesterol and apolipoprotein B, high-density-lipoprotein (HDL) cholesterol and apolipoprotein A1, and glucose and glycohemoglobin. During therapy with the higher dose, mean plasma triglyceride levels were reduced from 3.65 .+-. 0.35 mmol/L at baseline to 1.85 .+-. 0.20 mmol/L at 1 month, but increased by 30% to 2.40 .+-. 0.30 mmol/L by the third month of therapy (P < 0.05); this increase could not be explained by changes in body weight or compliance. Plasma triglyceride levels continued to increase with low-dose therapy and remained only 11% below baseline values by the sixth month of therapy (P = not significant). Although fish oil therapy increased HDL cholesterol levels (+ 18% at high dose, 99% CI, 5% to 31%), favorable changes were not seen in LDL cholesterol, apolipoprotein B, or apolipoprotein A1 levels. Conclusions: Fish oil concentrate at high doses followed by low-dose maintenance therapy cannot sustain the initial large plasma triglyceride reductions. Moreover, the efficacy of the higher dose becomes less pronounced after the first month of therapy. This reduced efficacy during prolonged therapy, and the lack of beneficial effect on apolipoprotein and LD cholesterol levels, may limit the practical benefit of fish oil in the treatment of hypertriglyceridemia.Keywords
This publication has 23 references indexed in Scilit:
- Effects of a Low Saturated Fat, Low Cholesterol Fish Oil Supplement in Hypertriglyceridemic PatientsAnnals of Internal Medicine, 1988
- Adverse Metabolic Effect of Omega-3 Fatty Acids in Non-Insulin-Dependent Diabetes MellitusAnnals of Internal Medicine, 1988
- Composition and distribution of low density lipoprotein fractions in hyperapobetalipoproteinemia, normolipidemia, and familial hypercholesterolemia.Proceedings of the National Academy of Sciences, 1983
- The Effect of N-6 and N-3 Polyunsaturated Fatty Acids on Hemostasis, Blood Lipids and Blood PressureThrombosis and Haemostasis, 1983
- Association of Hyperapobetalipoproteinemia with Endogenous Hypertriglyceridemia and AtherosclerosisAnnals of Internal Medicine, 1982
- Mechanism of hypertriglyceridaemia in diabetic patients with fasting hyperglycaemiaDiabetologia, 1980
- Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (beta) lipoproteins].Proceedings of the National Academy of Sciences, 1980
- MATHEMATICAL EVALUATION OF METHODS FOR ESTIMATION OF CONCENTRATION OF MAJOR LIPID COMPONENTS OF HUMAN-SERUM LIPOPROTEINS1976
- Fatty acid esterification and chylomicron formation during fat absorption: 1. Triglycerides and cholesterol estersJournal of Lipid Research, 1963
- A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUESJournal of Biological Chemistry, 1957